Basurto L, Balcázar-Hernández L, Madrid-Miller A

Idioma: Inglés [English version]
Referencias bibliográficas: 17
Paginas: s11-14
Archivo PDF: 156.14 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanism and clinical disease. Hypertension. 2021; 78: 1197-1205.

2. Wei GS, Coady SA, Goff DC Jr, Brancati FL, Levy D, Selvin E et al. Blood pressure and the risk of developing diabetes in African Americans and whites: ARIC, CARDIA, and the Framingham heart study. Diabetes Care. 2011; 34: 873-879.

3. Lodi E, Carollo A, Martinotti V, Modena MG. Hypertension and pharmacological therapy in women. High Blood Press Cardiovasc Prev. 2018; 25 (2): 147-150.

4. Yildiz M, Esenboga K, Oktay AA. Hypertension and diabetes mellitus: highlights of a complex relationship. Curr Opin Cardiol. 2020; 35: 397-404.

5. Gersh FL, O'Keefe J, Lavie CL, Henry CM. The renin-angiotensin-aldosterone system in postmenopausal women: the promise of hormone therapy. Mayo Clinic Proc. 2021; 96 (12): 3130-3141.

6. Ali W, Bakris GL. How to manage hypertension in people with diabetes. Am J Hypertens. 2020; 33 (10): 935-943.

7. de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017; 40 (9): 1273-1284.

8. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al. Cardiovascular disease and risk management: Standards of care in Diabetes-2023. Diabetes Care. 2023; 46 (Suppl 1): S158-S190.

9. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium-glucose co-transport-2 in- inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014; 16: 457-466.

10. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014; 8: 330-339.

11. Vilsboll T, Christensen M, Junker AE, Knop F, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomized controlled trials. BMJ. 2012; 344: d7771.

12. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA et al; ACCORD Study Group. Effects of intensive blood- pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1575-1585.

13. Buckley LF, Dixon DL, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassell BW. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. Diabetes Obes Metab. 2018; 20 (6): 1499-1502.

14. Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5 (12): 951-964.

15. Cífková R, Strilchuk L. Sex differences in hypertension. Do we need a sex-specific guideline? Front Cardiovasc Med. 2022; 9: 960336.

16. Gerdts E, de Simone G. Hypertension in women: should there be a sex-specific threshold? Eur Cardiol. 2021; 16: e38.

17. DiDudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: a novel phenotype of antihypertensive treatment failure. Hypertension. 2016; 67 (6): 1085-1092.